Sit Investment Associates’s Mereo BioPharma MREO Stock Holding History

Sit Investment Associates’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	970	–	–	﹤0.01%	529
2026 Q1	$0	Hold	970	–	–	﹤0.01%	524
2025 Q4	$0	Hold	970	–	–	﹤0.01%	529
2025 Q3	$2K	Hold	970	–	–	﹤0.01%	512
2025 Q2	$3K	Hold	970	–	–	﹤0.01%	519
2025 Q1	$2K	Hold	970	–	–	﹤0.01%	520
2024 Q4	$3K	Hold	970	–	–	﹤0.01%	528
2024 Q3	$4K	Hold	970	–	–	﹤0.01%	537
2024 Q2	$3K	Hold	970	–	–	﹤0.01%	532
2024 Q1	$3K	Hold	970	–	–	﹤0.01%	522
2023 Q4	$2K	Hold	970	–	–	﹤0.01%	533
2023 Q3	$1K	Hold	970	–	–	﹤0.01%	531
2023 Q2	$1K	Hold	970	–	–	﹤0.01%	545
2023 Q1	$1K	Hold	970	–	–	﹤0.01%	533
2022 Q4	$1K	Hold	970	–	–	﹤0.01%	541
2022 Q3	$1K	Hold	970	–	–	﹤0.01%	518
2022 Q2	$1K	Hold	970	–	–	﹤0.01%	513
2022 Q1	$1K	Hold	970	–	–	﹤0.01%	514
2021 Q4	$2K	Buy	+970	New	+$1.94K	﹤0.01%	512
2021 Q3	–	Sell	-970	Closed	-$3K	–	508
2021 Q2	$3K	Hold	970	–	–	﹤0.01%	527
2021 Q1	$3K	Hold	970	–	–	﹤0.01%	525
2020 Q4	$3K	Buy	+970	New	+$2.43K	﹤0.01%	520

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Sit Investment Associates's MREO Position: Q2 2026 in Review

Sit Investment Associates held its Mereo BioPharma (MREO) position steady in Q2 2026 at 970 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #529.

Sit Investment Associates first reported a position in MREO in Q4 2020 and has held it in 22 quarters since. The position peaked at $4K in Q3 2024. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Sit Investment Associates held 970 shares of Mereo BioPharma worth $0 as of Q2 2026.
Sit Investment Associates left its Mereo BioPharma share count unchanged in Q2 2026.
Mereo BioPharma made up ﹤0.01% of Sit Investment Associates's portfolio in Q2 2026, its #529 holding.
Sit Investment Associates first reported a position in Mereo BioPharma in Q4 2020 and has held it in 22 quarters since.
Sit Investment Associates's Mereo BioPharma position peaked at $4K in Q3 2024.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Sit Investment Associates's 13F filing for Q2 2026, filed 12 Aug 2026.